奥妥珠单抗治疗对利妥昔单抗继发性无应答的系统性红斑狼疮患者的疗效与安全性
该研究纳入9例对利妥昔单抗继发性无应答的系统性红斑狼疮患者,评估奥妥珠单抗(2×1000 mg输注联合甲泼尼龙100 mg)的疗效与安全性。6个月后SLEDAI-2K中位数从12降至6(P=0.014),BILAG-2004总分从21降至2(P=0.009),补体C3和dsDNA滴度均显著改善(均P=0.04)。作者认为奥妥珠单抗对这类重症患者似乎有效且具有激素节约作用。
要点
- 9例对利妥昔单抗继发性无应答的SLE患者接受奥妥珠单抗后6个月SLEDAI-2K和BILAG-2004评分显著下降。
- 8/9例基线口服泼尼松龙(均>10 mg/天)者中5/8在6个月时剂量减少,4/9例达到狼疮低疾病活动状态(LLDAS)。
- 1例未接种疫苗患者死于COVID-19,1例无应答者需环磷酰胺治疗。
核心结论
- 奥妥珠单抗对利妥昔单抗继发性无应答的肾脏和非肾脏SLE患者似乎有效并具有激素节约作用。
- 这类患者疾病严重且治疗选择有限,鉴于对B细胞清除的应答性,换用人源化2型抗CD20治疗是合理的策略。
研究设计与样本
- 研究汇总了BILAG中心中因对利妥昔单抗继发性无应答而接受奥妥珠单抗治疗的SLE患者数据。
- 共纳入9例患者,均接受奥妥珠单抗2×1000 mg输注联合甲泼尼龙100 mg,并同时使用口服免疫抑制剂。
- 在奥妥珠单抗前及后6个月采用BILAG-2004、SLEDAI-2K和血清学评估疾病活动度。
主要发现
- 奥妥珠单抗后6个月SLEDAI-2K中位数从12降至6(P=0.014),BILAG-2004总分从21降至2(P=0.009)。
- 补体C3和dsDNA滴度均显著改善(均P=0.04),C4水平有数值改善但未达统计学显著。
- 基线时8/9例口服泼尼松龙(均>10 mg/天),6个月时5/8例剂量减少;4/9例用量为5 mg/天并达到狼疮低疾病活动状态。
- 有外周B细胞数据的6/9例患者实现完全清除,包括4/4例采用高灵敏度检测评估者。
- 9例中1例奥妥珠单抗无应答者需环磷酰胺治疗,1例未接种疫苗患者死于COVID-19。
关键数值与推荐
- 对利妥昔单抗继发性无应答(secondary non-depletion nonresponse, 2NDNR)在重复接受利妥昔单抗疗程的SLE患者中发生率为14%。
- 奥妥珠单抗给药方案为2×1000 mg输注联合甲泼尼龙100 mg。
临床怎么用
- 作者认为,对利妥昔单抗继发性无应答的肾脏和非肾脏SLE患者,换用人源化2型抗CD20治疗是合理的策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Secondary inefficacy with infusion reactions and anti-drug antibodies (secondary non-depletion nonresponse, 2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy and safety of obinutuzumab, a next-generation humanized type-2 anti-CD20 antibody licensed for haematological malignancies in SLE patients with 2NDNR to rituximab. METHODS: We collated data from SLE patients receiving obinutuzumab for secondary non-response to rituximab in BILAG centres. Disease activity was assessed using BILAG-2004, SLEDAI-2K and serology before, and 6 months after, obinutuzumab 2× 1000 mg infusions alongside methylprednisolone 100 mg. RESULTS: All nine patients included in the study received obinutuzumab with concomitant oral immunosuppression. At 6 months post-obinutuzumab, there were significant reductions in median SLEDAI-2K from 12 to 6 (P = 0.014) and total BILAG-2004 score from 21 to 2 (P = 0.009). Complement C3 and dsDNA titres improved significantly (both P = 0.04). Numerical, but not statistically significant improvements were seen in C4 levels. Of 8/9 patients receiving concomitant oral prednisolone at baseline (all >10 mg/day), 5/8 had their dose reduced at 6 months. Four of nine patients were on 5 mg/day and were in Lupus Low Disease Activity State following obinutuzumab. After obinutuzumab, 6/9 patients with peripheral B cell data achieved complete depletion, including 4/4 assessed with highly sensitive assays. Of the nine patients, one obinutuzumab non-responder required CYC therapy. One unvaccinated patient died from COVID-19. CONCLUSIONS: Obinutuzumab appears to be effective and steroid-sparing in renal and non-renal SLE patients with secondary non-response to rituximab. These patients have severe disease with few treatment options but given responsiveness to B cell depletion, switching to humanized type-2 anti-CD20 therapy is a logical approach.
引用
- Arnold J, Dass S, Twigg S, et al. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Rheumatology (Oxford). 2022. PMID: 35266512. doi:10.1093/rheumatology/keac150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。